{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:29:25Z","timestamp":1790728165137,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA174714"],"award-info":[{"award-number":["R01CA174714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM103518"],"award-info":[{"award-number":["P20GM103518"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["G12MD007595"],"award-info":[{"award-number":["G12MD007595"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-14-1-0050"],"award-info":[{"award-number":["W81XWH-14-1-0050"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-14-1-0149"],"award-info":[{"award-number":["W81XWH-14-1-0149"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-14-1-0458"],"award-info":[{"award-number":["W81XWH-14-1-0458"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-15-1-0444"],"award-info":[{"award-number":["W81XWH-15-1-0444"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Developmental Fund of Tulane Cancer Center (TCC)"},{"name":"Louisiana Cancer Research Consortium (LCRC)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostate"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1002\/pros.23226","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T10:34:01Z","timestamp":1466591641000},"page":"1420-1430","source":"Crossref","is-referenced-by-count":23,"title":["Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth"],"prefix":"10.1002","volume":"76","author":[{"given":"David","family":"Cunningham","sequence":"first","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshab R.","family":"Parajuli","sequence":"additional","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changde","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Chemistry and RCMI Cancer Research Center; Xavier University of Louisiana; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemistry and RCMI Cancer Research Center; Xavier University of Louisiana; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"},{"name":"Department of Thoracic Surgery; West China Hospital\/West China School of Medicine; Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbing","family":"You","sequence":"additional","affiliation":[{"name":"Department of Structural and Cellular Biology; Tulane University; New Orleans Louisiana"},{"name":"Department of Orthopaedic Surgery; Tulane University; New Orleans Louisiana"},{"name":"Tulane Cancer Center; Louisiana Cancer Research Consortium; Tulane University; New Orleans Louisiana"},{"name":"Tulane Center for Stem Cell Research and Regenerative Medicine; Tulane University; New Orleans Louisiana"},{"name":"Tulane Center for Aging; Tulane University; New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"issue":"1","key":"10.1002\/pros.23226-BIB0001|pros23226-cit-0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1002\/pros.23226-BIB0002|pros23226-cit-0002","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"issue":"20 Pt 2","key":"10.1002\/pros.23226-BIB0003|pros23226-cit-0003","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skelmorbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1002\/pros.23226-BIB0004|pros23226-cit-0004","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","article-title":"Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies","volume":"194","author":"Crawford","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1002\/pros.23226-BIB0005|pros23226-cit-0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"Fitzpatrick","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1002\/pros.23226-BIB0006|pros23226-cit-0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1188\/12.CJON.286-291","article-title":"Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer","volume":"16","author":"Doyle-Lindrud","year":"2012","journal-title":"Clin J Oncol Nurs"},{"key":"10.1002\/pros.23226-BIB0007|pros23226-cit-0007","first-page":"651","article-title":"Advanced prostate cancer-Patient survival and potential impact of enzalutamide and other emerging therapies","volume":"10","author":"Patel","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1002\/pros.23226-BIB0008|pros23226-cit-0008","first-page":"97","article-title":"Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer","volume":"6","author":"Zobniw","year":"2014","journal-title":"Res Rep Urol"},{"key":"10.1002\/pros.23226-BIB0009|pros23226-cit-0009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semcancer.2015.08.005","article-title":"Therapy escape mechanisms in the malignant prostate","volume":"35","author":"Santer","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1002\/pros.23226-BIB0010|pros23226-cit-0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/pros.23226-BIB0011|pros23226-cit-0011","first-page":"559","article-title":"The use of radioactive phosphorus in the treatment of carcinoma of the breast and widespread metastases to the bone","volume":"64","author":"Friedell","year":"1950","journal-title":"Am J Roentgenol Radium Ther"},{"key":"10.1002\/pros.23226-BIB0012|pros23226-cit-0012","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00007611-195803000-00009","article-title":"The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate","volume":"51","author":"Maxfield","year":"1958","journal-title":"South Med J"},{"issue":"1","key":"10.1002\/pros.23226-BIB0013|pros23226-cit-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cbr.2013.1549","article-title":"Radiometabolic treatment of bone-metastasizing cancer: From 186rhenium to 223radium","volume":"29","author":"Rubini","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"10.1002\/pros.23226-BIB0014|pros23226-cit-0014","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pros.23226-BIB0015|pros23226-cit-0015","doi-asserted-by":"publisher","DOI":"10.1097\/COC0000000000000181","article-title":"Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies","author":"Dan","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1002\/pros.23226-BIB0016|pros23226-cit-0016","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1002\/pros.23226-BIB0017|pros23226-cit-0017","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.3892\/mmr.2015.3957","article-title":"Alendronate, a double-edged sword acting in the mevalonate pathway","volume":"12","author":"Tricarico","year":"2015","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1002\/pros.23226-BIB0018|pros23226-cit-0018","first-page":"1","article-title":"Molecular mechanisms of bone metastasis","volume":"13","author":"Weidle","year":"2016","journal-title":"Cancer Genomics Proteomics"},{"issue":"12","key":"10.1002\/pros.23226-BIB0019|pros23226-cit-0019","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-P","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1002\/pros.23226-BIB0020|pros23226-cit-0020","first-page":"529","article-title":"Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications","volume":"10","author":"Pettit","year":"1995","journal-title":"Anticancer Drug Des"},{"issue":"4","key":"10.1002\/pros.23226-BIB0021|pros23226-cit-0021","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"CAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1002\/pros.23226-BIB0022|pros23226-cit-0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMO.S6637","article-title":"Emerging pharmacotherapy for relapsed or refractory hodgkin's lymphoma: Focus on brentuximab vedotin","volume":"6","author":"Furtado","year":"2012","journal-title":"Clin Med Insights Oncol"},{"issue":"14","key":"10.1002\/pros.23226-BIB0023|pros23226-cit-0023","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-Expressing Breast cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1002\/pros.23226-BIB0024|pros23226-cit-0024","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/jco.2014.32.15_suppl.2504","article-title":"A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)","volume":"32","author":"Burris","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1002\/pros.23226-BIB0025|pros23226-cit-0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138161210789941801","article-title":"Mechanisms of drug-induced mitotic catastrophe in cancer cells","volume":"16","author":"Portugal","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1002\/pros.23226-BIB0026|pros23226-cit-0026","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cdd.2008.47","article-title":"Death through a tragedy: Mitotic catastrophe","volume":"15","author":"Vakifahmetoglu","year":"2008","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1002\/pros.23226-BIB0027|pros23226-cit-0027","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: A mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10.1002\/pros.23226-BIB0028|pros23226-cit-0028","first-page":"2577","article-title":"Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer","volume":"54","author":"Thalmann","year":"1994","journal-title":"Cancer Res"},{"issue":"9","key":"10.1002\/pros.23226-BIB0029|pros23226-cit-0029","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.18632\/oncotarget.7055","article-title":"Aminomethylphosphonic acid inhibits growth and metastasis of human prostate cancer in an orthotopic xenograft mouse model","volume":"7","author":"Parajuli","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1002\/pros.23226-BIB0030|pros23226-cit-0030","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: Image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol"},{"issue":"8","key":"10.1002\/pros.23226-BIB0031|pros23226-cit-0031","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/bioinformatics\/btr095","article-title":"Improved structure, function and compatibility for CellProfiler: Modular high-throughput image analysis software","volume":"27","author":"Kamentsky","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1002\/pros.23226-BIB0032|pros23226-cit-0032","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.b.33651","article-title":"Substituted hydroxyapatites for bone regeneration: A review of current trends","author":"Ratnayake","year":"2016","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"7","key":"10.1002\/pros.23226-BIB0033|pros23226-cit-0033","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/0008-5472.CAN-14-1931","article-title":"Tumor radiosensitization by monomethyl auristatin E: Mechanism of action and targeted delivery","volume":"75","author":"Buckel","year":"2015","journal-title":"Cancer Res"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23226","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pros.23226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:45:37Z","timestamp":1625460337000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23226"}},"subtitle":["MMAEp Inhibits Prostate Cancer"],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/pros.23226","archive":["Portico"],"relation":{},"ISSN":["0270-4137"],"issn-type":[{"value":"0270-4137","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,21]]}}}